Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Sisunatovir in Hepatic Impairment
NCT05857644Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jun 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sisunatovir in respiratory syncytial virus infection (RSV) (4 arms), sponsored by Pfizer. Primary endpoints: Plasma Maximum Concentration, Area Under the Plasma Concentration-time Profile (AUClast) and 1 more. Started Jun 2023; status: completed.
02
Drugs
sisunatovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT05857644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05857644.